Increased concentration of plasminogen activator inhibitor-1 and fibrinogen in individuals with metabolic syndrome

• Published in: Molecular medicine reports Vol. 2; no. 2; pp. 253 - 257
• Main Authors: Palomo, Iván G, Gutiérrez, César L, Alarcón, Marcelo L, Jaramillo, Julio C, Segovia, Fabián M, Leiva, Elba M, Mujica, Verónica E, Icaza, Gloria N, Díaz, Nora S, Moore-Carrasco, Rodrigo
• Format: Journal Article
• Language: English
• Published: Greece 01.03.2009
• ISSN: 1791-2997
• DOI: 10.3892/mmr_00000092

Metabolic syndrome (MS) is closely linked to a generalized metabolic disorder referred to as insulin resistance. Disturbances in the hemostasis and fibrinolytic systems are a feature of MS. The aim of this study was to determine the concentration levels of fibrinogen and plasminogen activator inhibitor-1 (PAI-1) in a group of patients with MS with respect to a non-MS group, and to evaluate their possible relation with other risk factors in MS. The study was carried out in a total of 186 male and female non-smoking individuals aged 45-64 years, 93 with MS (ATP III criteria) and 93 without MS. Plasmatic levels of PAI-1 were measured by ELISA, and those of fibrinogen by the Claus method. The plasmatic levels of PAI-1 (men 49.2±19.8 vs. 35.0±12.2 ng/ml and women 42.0±19.7 vs. 31.6±14.6 ng/ml; p=0.0026) and fibrinogen (274.0±82.1 vs. 232.7±66.6 ng/ml; p=0.0002) were significantly higher in the MS group than in the non-MS group. PAI-1 was significantly associated with diastolic blood pressure, triglycerides and waist circumference. Fibrinogen was negatively associated with HDL-c. High plasmatic levels of PAI-1 and fibrinogen contribute to the cardiovascular risk that characterizes individuals with MS.